Featured Conference
Prescription Drug Pricing 101 & 102
February 22 – 23, 2007 * Philadelphia, PA
For more information or to register, please visit the conference website.
Bring Your Questions for the CMS Keynote Speaker!
Relative to government payor programs, how confident are you that the critical pricing calculations youve made are correct?
PEA’s Prescription Drug Pricing 101 & 102 conference is an in-depth two-day meeting designed for professionals in pharmaceutical and biotechnology companies. This program will help you develop a strategy for accurate drug pricing calculations for government payor programs.
Join the industrys experts for an intensive two days of training:
Day One:
- Pre-Conference Workshop: Government Pricing Fundamentals
- Afternoon focus: Medicare: Parts B and D
Day Two:
- Morning focus: The Deficit Reduction Act, Medicaid Rebate Program, PHS 340B
- Afternoon focus: GSS FSS, VA / DoD, Fraud & Abuse, AWP Pricing Litigation
Summit Highlights
- Explore pricing methodologies & strategies for Prescription Drug Plans (PDPs), Medicare Advantage (MA) drug plans, Special Needs Plans, and more!
- Hear first-hand from experienced pharma and biotech gurus on effective drug pricing strategies
- Make sense of eligibility rules, auto-enrollment for dual eligibles, and the impact that the initial, annual, and special enrollment periods are having on industry pricing strategies
- Examine the pros and cons of implementing a drug list based on reference pricing vs prior-authorization restrictions
- Learn what your peers are thinking about, what they are doing to comply with recent changes, and most importantly, find out why!
- Discover the new opportunities that Special Needs Plans represent for manufacturers
- Learn how others are handling dispute resolution with the widespread claims of insufficient reimbursement for Part B outpatient drugs since the change to ASP
- Anticipate the impact of the DRA on the existing government price reporting environment, including 340B pricing structure
- Get an inside look at PAP programs and other alternatives for addressing the coverage gap
- Hear about first year experiences with request for formulary exceptions and prior authorization restrictions
- Find out how the “two drug” per category and class rule is being implemented in practice
- Discover whether commercial payers will really following Medicare’s change from AWP to ASP, and how this trend is likely to impact you
- Get up-to-speed on the latest pricing trends for federal purchasers
For more information or to register, please visit the conference website.
Key Opinion Leaders, Medical Science Liaisons, & CME
This Special Supplement to Pharma Markeing News is critical reading for pharmaceutical companies and physician education service providers wishing to understand the new roles of key opinion leader physicians (KOLs) and medical science liaisons (MSLs) in the physician education process.
Order and pay for this Special Supplement now using your credit card
ONLY $29.95
PDF file delivered to you by email (usually within minutes of placing your order):
If you wish to be pay by check or credit card off-line, please use:
Printable Order Form
